The TGA has commenced proceedings in the Federal Court of Australia against Mr Garry Sandy Vereb for alleged unlawful importation, advertising, manufacturing, and supply of therapeutic goods in contravention of the Therapeutic Goods Act 1989 (the Act).
The therapeutic goods include black salve, B17/laetrile, vitamin B15, Megazyme Forte, shiitake mushroom extract, ketones, and metabolic therapy packages (the products).
The TGA alleges that Mr Vereb made unlawful claims about the products’ ability to treat serious health conditions, including cancer. References to the treatment of serious diseases, conditions, alignments or defects are known as restricted or prohibited representations and are not permitted to be included in advertising for therapeutic goods unless an approval or permission is given by the TGA.
The products were not entered in the Australian Register of Therapeutic Goods (ARTG) and were allegedly imported, manufactured, supplied and advertised without the approvals, exemptions or other authority required under the Act.
The TGA is seeking declarations of contraventions and pecuniary penalties against Mr Vereb.
The TGA strongly advises consumers against purchasing or using black salve or B17/laetrile.
Black salve and B17/laetrile contain substances which are included in Schedule 10 of the Poisons Standard. Schedule 10 substances are considered so dangerous to health that they are prohibited from sale, supply and use in Australia.